Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder

Obstetrics and Gynecology

Volumn 100, Issue 6, 2002, Pages 1219-1229

  Halbreich, Uriel ^a,g   Bergeron, Richard ^b   Yonkers, Kimberly A ^c   Freeman, Ellen ^d   Stout, Anna L ^e   Cohen, Lee ^f  

^a UNIVERSITY AT BUFFALO   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SERTRALINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DOSE CALCULATION; DRUG TOLERANCE; FEMALE; HUMAN; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PREMENSTRUAL DYSPHORIC DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SCORING SYSTEM; SCREENING;

ADULT; AFFECTIVE SYMPTOMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUTEAL PHASE; MIDDLE AGED; PREMENSTRUAL SYNDROME; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; SERTRALINE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 0036897747     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(02)02326-8     Document Type: Article

References (34)

1. Ramcharan S., Love E.J., Fick G.H., Goldfien A. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women Attributable risk and risk factors . J Clin Epidemiol. 45:1992;377-392.
2. Wittchen H.U., Becker E., Lieb R., Krause P. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med. 32:2002;119-132.
3. Bloch M., Schmidt P.J., Rubinow D.R. Premenstrual syndrome Evidence for symptom stability across cycles . Am J Psychiatry. 154:1997;1741-1746.
4. Yonkers K.A., Halbriech U., Freeman E., Brown C., Endicott J., Frank E., et al. The Sertraline Premenstrual Dysphoric Collaborative Study Group. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA. 278:1997;983-988.
5. Pearlstein T.B., Halbreich U., Batzar E.D., Brown C.S., Endicott J., Frank E., et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry. 61:2000;101-109.
6. Hylan T.R., Sundell K., Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior Experience from the United States, United Kingdom, and France . J Womens Health Gend Based Med. 8:1999;1043-1052.
7. Kendler K.S., Karkowski L.M., Corey L.A., Neale M.C. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry. 155:1998;1234-1240.
8. Condon J.T. The premenstrual syndrome A twin study . Br J Psychiatry. 162:1993;481-486.
9. Rojansky N., Halbreich U., Zander K., Barkai A., Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. Gynecol Obstet Invest. 31:1991;146-152.
10. Bancroft J., Cook A., Davidson D., Bennie J., Goodwin G. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychol Med. 21:1991;305-312.
11. Ashby C.R., Carr L.A., Cook C.L., Steptoe M.M., Franks D.D. Alteration of platelet serotonergic mechanism and monoamine oxidase activity in premenstrual syndrome. Biol Psychiatry. 24:1988;225-233.
12. Steiner M., Yatham L.N., Coote M., Wilkins A., Lepage P. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder Is the fenfluramine challenge test still relevant? Psychiatry Res. 87:1999;107-115.
13. Kouri E.M., Halbreich U. State and trait serotonergic abnormalities in women with dysphoric premenstrual syndromes. Psychopharmacol Bull. 33:1997;767-770.
14. Schmidt P.J., Nieman L.K., Danaceau M.A., Adams L.F., Rubinow D.R. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 338:1998;209-216.
15. Halbreich U., Endicott J., Goldstein S., Nee J. Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand. 74:1986;576-586.
16. Dimmock P.W., Wyatt K.M., Jones P.W., O'Brien P.M. Efficacy of selective serotonin reuptake inhibitors in premenstrual syndrome A systematic review . Lancet. 356:2000;1131-1136.
17. Steiner M., Steinberg S., Stewart D., Carter D., Berger C., Reid R., et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med. 332:1995;1529-1534.
18. Freeman E.W., Rickels K., Sondheimer S.J., Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder A randomized controlled trial . Arch Gen Psychiatry. 56:1999;932-939.
19. Altshuler LL, Cohen LS, Moline ML, Kahn DA, Carpenter D, Docherty JP. Treatment of depression in women [review]. Postgrad Med 2001;1-107.
20. Mitwally MF, Kahn L, Halbreich U. Pharmacological management of premenstrual syndrome and dysphoric premenstrual syndrome. Expert Opin Pharmacother. In press.
21. Sundblad C., Hedberg M.A., Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome A placebo-controlled trial . Neuropsychopharmacology. 9:1993;133-145.
22. Freeman E.W., Rickels K., Arredondo F., Kao L.C., Pollack S.E., Sondheimer S.J. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol. 19:1999;3-8.
23. Halbreich U., Smoller J.W. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry. 58:1997;399-402.
24. Young S.A., Hurt P.H., Benedek D.M., Howard R.S. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase A randomized, double-blind, placebo-controlled crossover trial . J Clin Psychiatry. 59:1998;76-80.
25. Jermain D.M., Preece C.K., Sykes R.L., Kuehl T.J., Sulak P.J. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med. 8:1999;328-332.
26. Wikander I., Sundblad C., Andersch B., Dagnell I., Zylberstein D., Bengtsson F., et al. Citalopram in premenstrual dysphoria Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? J Clin Psychopharmacol. 18:1998;390-398.
27. First M.B., Frances A., Pincus H.A. DSM-IV handbook of differential diagnosis. 1995;American Psychiatric Press, Washington.
28. Endicott J., Harrison W. Daily Rating of Severity of Problems form. 1990;New York State Psychiatric Institute, Department of Research Assessment and Training, New York.
29. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, clinician version (SCID-CV). 1996;American Psychiatric Press, Washington.
30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:1960;56-62.
31. Guy W. ECDEU assessment manual for psychopharmacology. Department of Health, Education and Welfare publication no. (ADM) 76-338. 1976;U.S. Government Printing Office, Washington.
32. Weissman M.M., Bothwell S. Assessment of social adjustment by patient self-report. Arch Gen Psychiatry. 33:1976;1111-1115.
33. Endicott J., Nee J., Harrison W., Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire A new measure . Psychopharmacol Bull. 29:1993;321-326.
34. Pearlstein T.B., Frank E., Rivera-Tovar A., Thoft J.S., Jacobs E., Mieczkowski T.A. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. J Affect Disord. 20:1990;129-134.